Shanghai GenTech Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

Shanghai GenTech Co., Ltd. (SHSE:688596) Stock Rockets 28% But Many Are Still Ignoring The Company

Oct 01

A Piece Of The Puzzle Missing From Shanghai GenTech Co., Ltd.'s (SHSE:688596) 26% Share Price Climb

Mar 03

CEO

Shanghai GenTech heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hong Liang Zheng	CFO & Deputy GM	3.4yrs	CN¥1.69m	0.51% CN¥ 53.5m
Yue Chen	Deputy GM & Secretary	3.4yrs	CN¥1.59m	1.03% CN¥ 107.5m
Kecheng Shi	General Manager	3yrs	CN¥2.38m	0.77% CN¥ 80.3m

3.4yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 688596 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zhong Xin Fei	Independent Director	5.5yrs	CN¥120.00k	geen gegevens
Haiwen Xie	Director	4.7yrs	geen gegevens	geen gegevens
Yong Huang	Director	8.4yrs	CN¥1.26m	9.29% CN¥ 971.5m
Mingzheng Zhou	Chairman of the Board of Supervisors	3.4yrs	geen gegevens	geen gegevens
Feng Yu	Supervisor	8.5yrs	geen gegevens	0.50% CN¥ 52.3m
Rong Cui	Director	15.8yrs	CN¥1.09m	geen gegevens
Dong Lei Yu	Chairman	9.4yrs	CN¥1.92m	geen gegevens
Wenyan Hu	Independent Director	3.4yrs	CN¥60.00k	geen gegevens
Yue Liu	Independent Director	2.2yrs	geen gegevens	geen gegevens

5.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688596 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Shanghai GenTech Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shanghai GenTech Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.80 (vs CN¥0.45 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Shanghai GenTech Co., Ltd. (SHSE:688596) Stock Rockets 28% But Many Are Still Ignoring The Company

Shanghai GenTech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 19%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.53 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 50 million worth of its shares.

Shanghai GenTech Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sentiment Still Eluding Shanghai GenTech Co., Ltd. (SHSE:688596)

Price target decreased by 9.8% to CN¥46.00

Do Shanghai GenTech's (SHSE:688596) Earnings Warrant Your Attention?

New minor risk - Dividend sustainability

Shanghai GenTech's (SHSE:688596) Profits May Not Reveal Underlying Issues

First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.04 in 1Q 2023)

Shanghai GenTech Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Shanghai GenTech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Returns On Capital At Shanghai GenTech (SHSE:688596) Have Stalled

A Piece Of The Puzzle Missing From Shanghai GenTech Co., Ltd.'s (SHSE:688596) 26% Share Price Climb

Full year 2023 earnings: EPS exceeds analyst expectations

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 50 million worth of its shares.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.33 in 3Q 2022)

Price target decreased by 9.4% to CN¥52.00

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.19 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 12% to CN¥50.50

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.21 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanghai GenTech Co., Ltd. announced that it expects to receive CNY 300 million in funding

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 120 million worth of its shares.

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.17 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.07 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.48 (vs CN¥0.45 in FY 2019)

New 90-day low: CN¥15.90

Investor sentiment deteriorated over the past week

New 90-day low: CN¥18.86

New 90-day low: CN¥20.75

Shanghai GenTech Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd